Trial Profile
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Cevaretigene ritoparvovec (Primary)
- Indications Retinal dystrophies
- Focus Adverse reactions
- Sponsors MeiraGTx
- 10 Aug 2023 Status changed from active, no longer recruiting to completed.
- 10 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Jul 2023.
- 10 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2023.